Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial-Reference-Cited by-同舟云学术

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Published:2016-07 Issue:10043 Volume:388 Page:488-497
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Tap William D,Jones Robin L,Van Tine Brian A,Chmielowski Bartosz,Elias Anthony D,Adkins Douglas,Agulnik Mark,Cooney Matthew M,Livingston Michael B,Pennock Gregory,Hameed Meera R,Shah Gaurav D,Qin Amy,Shahir Ashwin,Cronier Damien M,Ilaria Robert,Conti Ilaria,Cosaert Jan,Schwartz Gary K

Funder

Eli Lilly and Company

Imclone

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Sarcoma immunotherapy: past approaches and future directions;D'Angelo;Sarcoma,2014

2. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systemic review;Sharma;BMC Cancer,2013

3. Management of soft-tissue sarcomas: an overview and update;Singer;Lancet Oncol,2000

4. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic softtissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

5. PICASSO 3: a phase 3 international randomized double blind placebo-controlled study of doxorubicin plus palifosfamide vs. doxorubicin plus placebo for patients in first-line for metastatic soft tissue sarcoma;Ryan;Eur J Cancer,2013

Cited by 506 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

2. Functional and clinical roles of stromal PDGF receptors in tumor biology;Cancer and Metastasis Reviews;2024-07-09

3. UNC5B Knockdown Enhances Chemotherapy Sensitivity and Immunogenic Cell Death in Sarcoma: A Comprehensive Prognostic Analysis based on PANoptosis and Macrophage;2024-07-03

4. Long Duration Pembrolizumab for Metastatic Undifferentiated Pleomorphic Soft Tissue Sarcoma With Multimodality Therapy;Journal of Medical Cases;2024-07

5. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial.;Translational Oncology;2024-07